Linker Information
General Information of This Linker
| Linker ID |
LIN0VPGPE
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
Mal-Ile-Pro
|
|||||
| Linker Type |
Cathepsin-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C20H31N5O5
|
|||||
| Isosmiles |
CCC(C)C(NC(=O)C1CCCN1)C(=O)NCCNC(=O)CCN1C(=O)C=CC1=O
|
|||||
| InChI |
InChI=1S/C20H31N5O5/c1-3-13(2)18(24-19(29)14-5-4-9-21-14)20(30)23-11-10-22-15(26)8-12-25-16(27)6-7-17(25)28/h6-7,13-14,18,21H,3-5,8-12H2,1-2H3,(H,22,26)(H,23,30)(H,24,29)
|
|||||
| InChIKey |
IBRPUYJXRSMJDH-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
421.498
|
Polar area
|
136.71
|
||
|
Complexity
|
30
|
xlogp Value
|
-1.1832
|
|||
|
Heavy Count
|
30
|
Rot Bonds
|
11
|
|||
|
Hbond acc
|
6
|
Hbond Donor
|
4
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
1F6-Ile-Pro-AF [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
95.00% (Day 30)
|
Positive TNF expression (TNF+++/++) | ||
| Method Description |
3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
|
||||
| In Vivo Model | DBTRG-05MG glioblastoma cell line xenograft model | ||||
| In Vitro Model | Anaplastic astrocytoma | DBTRG-05MG cells | CVCL_1169 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
98.65% (Day 30)
|
Positive TNF expression (TNF+++/++) | ||
| Method Description |
3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
|
||||
| In Vivo Model | 786-O human RCC cell line xenograft model | ||||
| In Vitro Model | Renal cell carcinoma | 786-O cells | CVCL_1051 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
5.00 ng/mL
|
Positive TNF expression (TNF+++/++) | ||
| Method Description |
IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
|
||||
| In Vitro Model | Hodgkin lymphoma | L-428 cells | CVCL_1361 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
9.00 ng/mL
|
Positive TNF expression (TNF+++/++) | ||
| Method Description |
IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
|
||||
| In Vitro Model | Clear cell renal cell carcinoma | Caki-1 cells | CVCL_0234 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
10.00 ng/mL
|
Positive TNF expression (TNF+++/++) | ||
| Method Description |
IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
|
||||
| In Vitro Model | Renal cell carcinoma | 786-O cells | CVCL_1051 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.